Prostate Specific Antigen (PSA), Total
Prostate-specific antigen (PSA) is a serine protease glycoprotein that is secreted by the prostate gland. It is present in seminal fluid as well as blood. Its function is to help liquefy the semen; it is normally detectable in small amounts in the blood of all males. It is typically not detectable in women. Normally, PSA levels are very low but when prostate or urethra tissue is swollen or damaged, PSA is secreted in higher amounts. PSA level is used as a screening test for the early detection of prostate cancer in both symptomatic and asymptomatic males.
The use of PSA to detect early prostate cancer is controversial and trials are being performed to determine risks versus advantages. Typically men over the age of 50 should be screened annually for the presence of elevated PSA. Men who are more at risk due to genetic and family history can be screened at a younger age or more frequently. Long-term serial assays are used to follow response to therapy and to detect recurrent disease. A decrease in mortality rates from PSA screening has not yet been determined. Typically, elevated PSA would be followed by free PSA assay and prostate biopsy to diagnose prostate cancer. Treatment would be based on the results of the biopsy. PSA levels correlate well with tumor recurrence in men previously diagnosed and treated for prostate cancer. PSA results are also increased in benign prostatic hyperplasia (BPH), prostatitis, or as a result of urethral instrumentation. Laboratory testing for free and total PSA and the ratio in comparison to total PSA itself is more specific for prostate cancer and can improve diagnosis.
- Screen for prostatic carcinoma
- Assessing treatment response and monitoring for recurrence of disease
Increased in:
- Carcinoma of the Prostate
- Biochemical recurrence after localized treatment
- Benign prostatic hypertrophy (BPH)
- Prostatitis
- Urinary Retention
- Prostatic Biopsy
- Testosterone Administration
- Certain non-prostatic conditions (Hepatitis A, Breast or Renal Cell Carcinoma, Parotid Disorders)
Decreased in:
- Metastatic prostate carcinoma treated with antiandrogen therapy
- Post prostatectomy
- 5α-reductase inhibitor therapy
- Low testosterone
< 4.0 ng/mL (mcg/L)
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum (SST) or plasma (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Clin Lab. 2005;51:127. [PMID: 15819167]
- Curr Urol Rep. 2005;6:307. [PMID: 15978235]
- Scand J Urol Nephrol Suppl. 2005;(216):64. [PMID: 16019759]
- J Urol. 2006;176:868. [PMID: 16890642]
- Urol Clin North Am. 2006;33:147. [PMID: 16631453]
- Jacobs DS and DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001).
- Prostate Specific Antigen (PSA), Serum. In Mayo Interpretive Handbook.Rochester: Mayo Medical Laboratories (2009).
- Revision: David A. Swanson, MD. (2007, December). Prostate Cancer. Retrieved October 11, 2010, from Merck Manuals Online Library: www.merck.com